A 32-year-old woman from rural Maharashtra presents with vaginal bleeding and lower abdominal pain 6 months after evacuation of a molar pregnancy. Ultrasound shows a heterogeneous mass in the uterus with myometrial invasion. Serum β-hCG is 8,500 mIU/mL. Regarding the management and prognosis of this condition, all of the following are appropriate EXCEPT:

## Clinical Presentation and Diagnosis of Invasive Mole **Key Point:** This patient has invasive mole (chorioadenoma destruens) — a locally invasive form of GTD that penetrates the myometrium. The diagnosis is based on: - History of molar pregnancy - Persistent elevation of β-hCG (>5 mIU/mL) after evacuation - Imaging evidence of myometrial invasion - Absence of distant metastases ### WHO Risk Stratification for GTD This patient is **LOW-RISK** based on: - Age 32 years (<40 years) - Interval from evacuation 6 months (12 months is threshold) - β-hCG 8,500 mIU/mL (<100,000 mIU/mL) - No evidence of metastases on imaging - Invasive mole (lower malignant potential than choriocarcinoma) **High-Yield:** WHO score ≤6 = low-risk disease; >6 = high-risk disease. Low-risk GTN has >95% cure rate with single-agent chemotherapy. ## Management Algorithm for Low-Risk GTD ```mermaid flowchart TD A[GTD diagnosed]:::outcome --> B[Staging: CXR, pelvic MRI/CT]:::action B --> C{Metastases?}:::decision C -->|No| D[Low-risk GTN]:::outcome C -->|Yes| E[High-risk GTN]:::outcome D --> F[Single-agent chemotherapy]:::action F --> G[Methotrexate or Dactinomycin]:::action G --> H[Weekly β-hCG monitoring]:::action H --> I{hCG normalized?}:::decision I -->|Yes| J[Continue chemotherapy 1-2 cycles post-normalization]:::action I -->|No| K[Escalate to multi-agent regimen]:::action J --> L[Monthly hCG monitoring for 6-12 months]:::action L --> M[Cure achieved]:::outcome E --> N[Multi-agent chemotherapy: EMA-CO]:::action ``` **Clinical Pearl:** Hysterectomy is NOT the primary treatment for invasive mole in women of reproductive age. Chemotherapy is highly effective and preserves fertility. Hysterectomy is reserved for: - Failure of chemotherapy - Perforation with life-threatening hemorrhage - Women who have completed childbearing ### Why Option 2 Is INCORRECT Hysterectomy should NOT be performed immediately as the primary intervention. Invasive mole responds excellently to chemotherapy, and surgery should be avoided in reproductive-age women to preserve fertility. Hysterectomy is a salvage procedure for chemotherapy-resistant disease or emergency management of perforation/hemorrhage — not first-line treatment. ## Chemotherapy Protocols for Low-Risk GTD | Agent | Dosing | Route | Advantages | Disadvantages | | --- | --- | --- | --- | --- | | **Methotrexate** | 1 mg/kg IV/IM days 1, 3, 5, 7 | IV/IM | First-line, well-tolerated | Requires folinic acid rescue | | **Dactinomycin** | 12 μg/kg IV daily × 5 days | IV | Alternative if MTX resistance | More myelosuppression | | **Combination (EMA-CO)** | Etoposide, MTX, dactinomycin, cyclophosphamide, vincristine | IV | High-risk disease | Severe toxicity | **High-Yield:** For low-risk GTD, single-agent chemotherapy (methotrexate or dactinomycin) achieves cure in >95% of cases. Multi-agent regimens (EMA-CO) are reserved for high-risk disease. ## Follow-Up and Monitoring **Key Point:** β-hCG monitoring is the cornerstone of GTD follow-up: 1. **During chemotherapy:** Weekly β-hCG levels 2. **After normalization:** Continue chemotherapy for 1–2 additional cycles 3. **Post-chemotherapy:** Monthly β-hCG for 6–12 months 4. **Contraception:** Essential during monitoring (hCG can be elevated in pregnancy) **Warning:** Do NOT discontinue chemotherapy immediately upon β-hCG normalization — continued cycles reduce relapse risk from ~20% to <5%. ## Why Each Option Is Correct or Incorrect **Option 0 (Correct):** Staging with CXR and pelvic MRI/CT is mandatory before treatment to exclude metastatic disease and determine risk category. **Option 1 (Correct):** Single-agent chemotherapy (methotrexate or dactinomycin) is first-line for low-risk GTD and has >95% cure rate. **Option 2 (INCORRECT — THE ANSWER):** Hysterectomy is NOT the primary treatment. It is a salvage procedure for chemotherapy failure or emergency management of perforation. Chemotherapy is first-line and preserves fertility. **Option 3 (Correct):** Weekly hCG monitoring during chemotherapy and monthly monitoring for 6–12 months post-normalization is standard practice.